vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and BayCom Corp (BCML). Click either name above to swap in a different company.

BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $13.0M, roughly 2.0× Aquestive Therapeutics, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -244.8%, a 271.3% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-8.6M). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs 2.9%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

AQST vs BCML — Head-to-Head

Bigger by revenue
BCML
BCML
2.0× larger
BCML
$25.9M
$13.0M
AQST
Growing faster (revenue YoY)
AQST
AQST
+0.3% gap
AQST
9.7%
9.4%
BCML
Higher net margin
BCML
BCML
271.3% more per $
BCML
26.5%
-244.8%
AQST
More free cash flow
BCML
BCML
$38.6M more FCF
BCML
$30.1M
$-8.6M
AQST
Faster 2-yr revenue CAGR
AQST
AQST
Annualised
AQST
3.9%
2.9%
BCML

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AQST
AQST
BCML
BCML
Revenue
$13.0M
$25.9M
Net Profit
$-31.9M
$6.9M
Gross Margin
55.2%
Operating Margin
-221.6%
36.6%
Net Margin
-244.8%
26.5%
Revenue YoY
9.7%
9.4%
Net Profit YoY
-86.8%
12.1%
EPS (diluted)
$-0.26
$0.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
BCML
BCML
Q4 25
$13.0M
$25.9M
Q3 25
$12.8M
$25.7M
Q2 25
$10.0M
$24.7M
Q1 25
$8.7M
$24.3M
Q4 24
$11.9M
$23.7M
Q3 24
$13.5M
$25.6M
Q2 24
$20.1M
$23.8M
Q1 24
$12.1M
$24.5M
Net Profit
AQST
AQST
BCML
BCML
Q4 25
$-31.9M
$6.9M
Q3 25
$-15.4M
$5.0M
Q2 25
$-13.5M
$6.4M
Q1 25
$-22.9M
$5.7M
Q4 24
$-17.1M
$6.1M
Q3 24
$-11.5M
$6.0M
Q2 24
$-2.7M
$5.6M
Q1 24
$-12.8M
$5.9M
Gross Margin
AQST
AQST
BCML
BCML
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Q1 24
63.6%
Operating Margin
AQST
AQST
BCML
BCML
Q4 25
-221.6%
36.6%
Q3 25
-89.6%
26.3%
Q2 25
-113.6%
35.3%
Q1 25
-222.1%
31.6%
Q4 24
-114.4%
34.2%
Q3 24
-61.2%
32.4%
Q2 24
0.3%
31.9%
Q1 24
-74.3%
33.3%
Net Margin
AQST
AQST
BCML
BCML
Q4 25
-244.8%
26.5%
Q3 25
-120.6%
19.5%
Q2 25
-135.4%
25.8%
Q1 25
-263.0%
23.4%
Q4 24
-143.7%
25.9%
Q3 24
-85.0%
23.5%
Q2 24
-13.7%
23.6%
Q1 24
-106.4%
24.0%
EPS (diluted)
AQST
AQST
BCML
BCML
Q4 25
$-0.26
$0.63
Q3 25
$-0.14
$0.46
Q2 25
$-0.14
$0.58
Q1 25
$-0.24
$0.51
Q4 24
$-0.18
$0.55
Q3 24
$-0.13
$0.54
Q2 24
$-0.03
$0.50
Q1 24
$-0.17
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
BCML
BCML
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$338.6M
Total Assets
$160.4M
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
BCML
BCML
Q4 25
Q3 25
$129.1M
Q2 25
$60.5M
Q1 25
$68.7M
Q4 24
$71.5M
Q3 24
$77.9M
Q2 24
$89.9M
Q1 24
$95.2M
Total Debt
AQST
AQST
BCML
BCML
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
Q1 24
$45.0M
Stockholders' Equity
AQST
AQST
BCML
BCML
Q4 25
$-33.7M
$338.6M
Q3 25
$-4.1M
$334.3M
Q2 25
$-72.6M
$330.6M
Q1 25
$-60.9M
$329.3M
Q4 24
$-60.2M
$324.4M
Q3 24
$-45.4M
$321.7M
Q2 24
$-35.5M
$315.3M
Q1 24
$-36.3M
$314.2M
Total Assets
AQST
AQST
BCML
BCML
Q4 25
$160.4M
$2.6B
Q3 25
$163.6M
$2.6B
Q2 25
$93.7M
$2.6B
Q1 25
$102.2M
$2.6B
Q4 24
$101.4M
$2.7B
Q3 24
$110.0M
$2.6B
Q2 24
$117.6M
$2.6B
Q1 24
$129.5M
$2.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
BCML
BCML
Operating Cash FlowLast quarter
$-8.5M
$31.8M
Free Cash FlowOCF − Capex
$-8.6M
$30.1M
FCF MarginFCF / Revenue
-65.7%
116.2%
Capex IntensityCapex / Revenue
0.7%
6.7%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$-53.0M
$51.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
BCML
BCML
Q4 25
$-8.5M
$31.8M
Q3 25
$-12.6M
$7.3M
Q2 25
$-7.9M
$6.4M
Q1 25
$-23.4M
$9.3M
Q4 24
$-6.5M
$30.4M
Q3 24
$-11.9M
$9.6M
Q2 24
$-7.0M
$7.7M
Q1 24
$-10.4M
$5.1M
Free Cash Flow
AQST
AQST
BCML
BCML
Q4 25
$-8.6M
$30.1M
Q3 25
$-12.9M
$6.2M
Q2 25
$-8.0M
$5.6M
Q1 25
$-23.5M
$9.1M
Q4 24
$-6.5M
$28.7M
Q3 24
$-12.0M
$9.4M
Q2 24
$-7.0M
$7.4M
Q1 24
$-10.4M
$3.9M
FCF Margin
AQST
AQST
BCML
BCML
Q4 25
-65.7%
116.2%
Q3 25
-100.6%
24.3%
Q2 25
-80.2%
22.8%
Q1 25
-269.9%
37.6%
Q4 24
-54.8%
121.1%
Q3 24
-88.3%
36.6%
Q2 24
-35.0%
31.2%
Q1 24
-86.4%
16.1%
Capex Intensity
AQST
AQST
BCML
BCML
Q4 25
0.7%
6.7%
Q3 25
1.8%
4.3%
Q2 25
1.1%
3.0%
Q1 25
1.5%
0.6%
Q4 24
0.1%
7.2%
Q3 24
0.6%
1.0%
Q2 24
0.2%
1.0%
Q1 24
0.2%
4.7%
Cash Conversion
AQST
AQST
BCML
BCML
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
Q2 24
1.37×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons